Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
69actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-12 | actual | When the study began enrolling |
| Primary completion | 2026-05-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-27 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Endocrinology
- Diabetes, Type II
- Obesity
Interventions
- Drug: AZD6234
- Drug: Placebo to match
Primary outcomes
what the primary-completion date above is the date OFPercent change in body weight from baseline at Study Week 26
measured From baseline to week 26
Weight loss ≥ 5% from baseline at Study Week 26
measured From baseline to week 26
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed